0.42
-0.74%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Scisparc
Its shares trade under the ticker SPRC. It has been listed since 22 December 2021. In the fiscal year to 31 December 2025, it reported revenue of $856,000 and a net loss of $12.2m. At that date it held total assets of $7.6m and shareholders' equity of $4.2m.
SciSparc Ltd. is a clinical stage pharmaceutical company, which focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The firm is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 22 Dec 2021
- Employees
- 3
- Website
- scisparc.com ↗
- Head office
- 20 RAUL WALLENBERG STREET, TOWER A, TEL AVIV, L3, 6971916
- Incorporated in
- L3
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer
Leadership
Pay as last reported
- Mr. Itschak ShremChairman of the Board, since 2020
- Mr. Amitay WeissChief Executive Officer, Director, since 2020
- Mr. Oz AdlerChief Financial Officer$301,000
- Dr. Adi Zuloff-ShaniChief Technology Officer$214,000
- Mr. Moshe RevachDirector
- Ms. Liat SidiDirector
- Mr. Alon DayanIndependent Director
- Prof. Ari ShamissIndependent Director
- Mr. Amnon ShayIndependent Director
- Mr. Lior ViderIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company has a focused portfolio on cannabinoid pharmaceuticals for multiple conditions.
- Operates as a clinical stage pharmaceutical company with specific drug development programs.
- Maintains a small team of three employees with a clear focus on drug development.
Weaknesses
- Limited employee count of only three individuals may hinder operational capacity.
- Company is in the clinical stage with no commercialized products yet.
- Small size may limit access to significant capital for research and development.
Opportunities
- Potential for drug development programs to address unmet medical needs in Tourette syndrome and sleep apnea.
- Repurposing existing cannabinoid compounds could reduce development costs and time.
- Growing interest in cannabinoid-based treatments may attract investment and partnerships.
Threats
- Regulatory challenges in the cannabinoid pharmaceutical sector may delay approvals.
- Competition from larger pharmaceutical companies in the same therapeutic areas.
- Market volatility in biotechnology could impact funding and investor confidence.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.